<DOC>
	<DOCNO>NCT00017121</DOCNO>
	<brief_summary>RATIONALE : Inhaling sargramostim may interfere growth tumor cell may effective treatment melanoma spread lung . PURPOSE : This phase I trial study side effect best dose inhaled sargramostim treat patient melanoma metastatic lung .</brief_summary>
	<brief_title>Inhaled Sargramostim Treating Patients With Melanoma Metastatic Lung</brief_title>
	<detailed_description>OBJECTIVES : - Determine immunomodulatory effect aerosolize sargramostim ( GM-CSF ) patient metastatic melanoma lung ( part A ) . - Determine toxicity profile therapy , term pulmonary hematologic toxicity , patient . - Determine , preliminarily , therapeutic effect therapy , term progression-free survival , overall survival , objective response rate , patient . - Determine maximum tolerate dose GM-CSF patient ( part B ) . OUTLINE : This dose-escalation , multicenter study . Patients receive aerosolize sargramostim ( GM-CSF ) twice day day 1-7 15-21 . Treatment repeat every 28 day 2 course . Patients disease progression completion course 2 may continue treatment disease progression . Patients group 1 2 dose-escalation regimen ( part A v B ) . - Part A : Cohorts 5-10 patient receive escalate dos GM-CSF optimal immunostimulatory dose ( ISD ) determine . The optimal ISD define dose least 7 10 patient experience immunostimulation . Once optimal ISD determine , 10 patient receive aerosolize GM-CSF dose halfway optimal ISD precede dose . Dose escalation discontinue least 2 5 least 4 10 patient particular dose level experience dose-limiting toxicity . - Part B : Cohorts 3-6 patient receive escalate dos GM-CSF maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . At least 6 patient treated MTD . After completion study therapy , patient follow 3 month , every 2 month 1 year , every 3-4 month 5 year . PROJECTED ACCRUAL : A total 85 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic melanoma lung know standard therapy exist At least 1 unidimensionally measurable lesion HLAA2 positive ( part A patient ) Previously treat CNS metastasis allow provided evidence disease progression within past 3 month PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,000/mm^3 Platelet count least 75,000/mm^3 Hemoglobin least 8.0 g/dL Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) AST great 3 time ULN Renal : Creatinine great 2.5 time ULN Cardiovascular : No New York Heart Association class III IV heart disease Pulmonary : No pulmonary disease require concurrent active therapy ( e.g. , supplemental oxygen bronchodilator ) FEV_1 least 65 % predict least 1.5 L Immunologic : No known immunodeficiency state No known autoimmune disease No uncontrolled infection Other : No active psychotic disorder require pharmacotherapy Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : More 2 week since prior biologic therapy More 2 week since prior immunotherapy More 4 week since prior filgrastim ( GCSF ) sargramostim ( GMCSF ) No concurrent biologic therapy immunotherapy No concurrent GCSF No concurrent GMCSF study drug Chemotherapy : More 3 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) No concurrent chemotherapy Endocrine therapy : More 2 week since prior corticosteroid No concurrent glucocorticosteroids Radiotherapy : More 2 week since prior radiotherapy No concurrent radiotherapy Surgery : Not specify Other : More 7 day since prior parenteral antibiotic No concurrent parenteral antibiotic No concurrent immunosuppressive agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>lung metastasis</keyword>
</DOC>